EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access

Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848

Ross A Abrams iD, Kathryn A Winter, Karyn A Goodman iD, William F Regine, Howard P Safran iD, Chandan S Guha iD, Lisa A Kachnic iD, Michael T Gillin, Philip A Philip iD, Andrew M Lowy iD, Eileen O'Reilly iD, Jean-Luc Van Laethem und 12 weitere

Journal of Clinical Oncology · 20.08.2026 · 44 (24) · 2316-2328

DOI: 10.1200/jco-25-02520 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.08.2026. Verfasst von Ross A Abrams und 23 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology, Retired-Rush University Medical Center, Professor Emeritus, Chicago, IL. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To assess whether adding fluoropyrimidine sensitized radiotherapy (CXRT) to adjuvant chemotherapy improves overall survival (OS) after curative intent resection of the pancreatic head. METHODS This was a multicenter, randomized phase III, two step trial. Step 1: gemcitabine versus gemcitabine + erlotinib (previously reported). Step 2: random assignment to sixth chemotherapy cycle ± CXRT after five cycles of step 1 chemotherapy without progression. Outcomes of step 2 random assignment are reported here. Assuming 17 months median OS (chemotherapy alone), the sample size was 354 patients (hazard ratio [HR], 0.76, 80% power, one-sided α = .05, 316 OS events). OS/disease-free survival (DFS) were estimated by Kaplan-Meier and arms compared using the log-rank test. RESULTS A total of 354 patients (median age 63, 55% male, 56% performance status, 1) were randomly assigned to chemotherapy (174) or chemotherapy + CXRT (180). Univariable median and 5-year OS (90% CIs) were 2.6 years (2.1-3.1) and 23.1% (17.7-28.6) for chemotherapy alone, and 2.3 years (2.0-2.6) and 27.9% (22.2-33.6) for chemotherapy + CXRT. The OS primary end point was not met (HR, 0.96 [90% CI, 0.79 to 1.18]; one-sided P = .38, two-sided P = .77). Chemotherapy + CXRT was associated with a trend for improved DFS (univariably; HR, 0.82 [95% CI, 0.65 to 1.03]; P = .089), without increase in grade 4/5 toxicities. However, grade 3 toxicity increased (38% v 19%, P < .001). Significantly, treatment by nodal status interactions showed that CXRT improved OS ( P = .0063) and DFS ( P = .014) in node-negative patients. CONCLUSION Overall, the addition of adjuvant CXRT to adjuvant gemcitabine did not statistically significantly improve OS, DFS, or increase grade 4/5 toxicity. For node-negative patients, CXRT improved OS and DFS. These results, if confirmed in studies with current or future systemic therapies, would support the use of adjuvant/neoadjuvant CXRT for node-negative patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAdenocarcinomaHumansFemaleMaleChemotherapy, AdjuvantGemcitabineDeoxycytidineMiddle AgedErlotinib HydrochlorideAgedDisease-Free SurvivalAdult

Substanzen

GemcitabineDeoxycytidineErlotinib Hydrochloride

Autor:innen und Institutionen

  • Radiation Oncology, Retired-Rush University Medical Center, Professor Emeritus, Chicago, IL.
  • Department of Statistics, NRG Oncology Statistics and Data Management Center, Philadelphia, PA.
  • Department of Statistics, American College of Radiology, Philadelphia, PA.
  • Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Department of Radiation Oncology, University of Maryland School of Medicine and Greenebaum Cancer, Baltimore, MD.
  • Department of Hematology/Oncology, Rhode Island Hospital, Providence, RI.

ORCID-Profile: Ross A Abrams, Karyn A Goodman, Howard P Safran, Chandan S Guha, Lisa A Kachnic, Philip A Philip, Andrew M Lowy, Eileen O'Reilly, Samantha A Seaward, Abraham J Wu, Jennifer J Wu, Ravit Geva, Darla K Liles, Christopher H Crane

Förderung

  • NCI NIH HHS

Zitieren

APA

Abrams, R. A., Winter, K. A., Goodman, K. A., Regine, W. F., Safran, H. P., Guha, C. S., Kachnic, L. A., Gillin, M. T., Philip, P. A., Lowy, A. M., O'Reilly, E., Van Laethem, J. L., Seaward, S. A., Wu, A. J., Wu, J. J., Aljumaily, R. M., DiPetrillo, T. A., Geva, R., Anne, P. R., …, & Crane, C. H. (2026). Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848. Journal of Clinical Oncology, 44(24), 2316-2328. https://doi.org/10.1200/jco-25-02520

Vancouver

Abrams RA, Winter KA, Goodman KA, Regine WF, Safran HP, Guha CS, et al. Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848. Journal of Clinical Oncology. 2026;44(24):2316-2328. doi:10.1200/jco-25-02520

BibTeX
@article{Abrams2026,
  author = {Abrams, Ross A and Winter, Kathryn A and Goodman, Karyn A and Regine, William F and Safran, Howard P and Guha, Chandan S and Kachnic, Lisa A and Gillin, Michael T and Philip, Philip A and Lowy, Andrew M and O'Reilly, Eileen and Van Laethem, Jean-Luc and Seaward, Samantha A and Wu, Abraham J and Wu, Jennifer J and Aljumaily, Raid M and DiPetrillo, Thomas A and Geva, Ravit and Anne, Pramila Rani and Liles, Darla K and Ling, Diane C and Conlin, Alison and Moughan, Jennifer and Crane, Christopher H},
  title = {Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {24},
  pages = {2316--2328},
  doi = {10.1200/jco-25-02520}
}
Kostenlos starten →